COVID-19 Vaccine Booster Provides Good Antibody Protection Against Omicron, Researchers Find

A third ‘booster’ dose of COVID-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Wednesday) as a Research letter in The Lancet.


Researchers found that antibodies generated in people who had received only two doses of either the Oxford/AstraZeneca vaccine or the Pfizer/BioNTech vaccine were less able to neutralise the Omicron variant as compared to the Alpha and Delta variants.*

They also found that antibody levels dropped off in the first three months following the second dose but that a third ‘booster’ dose raised levels of antibodies that effectively neutralise the Omicron variant.

In people who had received the Pfizer/BioNTech vaccine for all three doses, antibody levels against Omicron after a third dose were similar to those previously reached against Delta after only two doses.** Overall, antibody levels were nearly 2.5x higher against Omicron after three doses compared to after two.***

Higher levels of antibodies against the Omicron variant were also found in people who received two doses of either vaccine and also reported previously having COVID-19 symptoms, compared to those had not previously had COVID-19 symptoms.

Whilst levels of antibodies alone do not predict vaccine effectiveness, they are a very good indicator of protection against severe COVID-19. This study confirms that three doses of COVID-19 vaccine are essential to boost antibodies to quantifiable levels and maximise the amount of protection against severe disease and hospitalisation. 

Researchers have submitted their findings to the Genotype-to-Phenotype National Virology Consortium (G2P-UK), the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunisation (JCVI).  

As part of the SARS-CoV-2 Legacy study, led by the Crick and partners at UCL and University College London Hospitals NHS Foundation Trust (UCLH), healthcare workers and staff from the institutions have been donating regular blood and swab samples so that researchers can track changing risk of infection and response to vaccination. 

The Legacy team analysed 620 blood samples from 364 people who enrolled in the study. They used robust high throughput viral neutralisation assays, developed at the Crick, to test the ability of antibodies to block entry of the virus into cells, so called ‘neutralising antibodies’, against different variants of SARS-CoV-2, including Omicron.